PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
35.97%
Net income growth 1.25-1.5x AGEN's 25.15%. Bruce Berkowitz would verify whether cost discipline or revenue gains drive the outperformance.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Well above AGEN's 100.00% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
-6.03%
Both cut yoy SBC, with AGEN at -3.98%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-150.99%
Both reduce yoy usage, with AGEN at -112.32%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-123.01%
Both negative yoy AP, with AGEN at -228.41%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-179.37%
Both reduce yoy usage, with AGEN at -37.77%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-42.60%
Both negative yoy, with AGEN at -173.01%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-14.43%
Both yoy CFO lines are negative, with AGEN at -128.51%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both yoy lines negative, with AGEN at -73.80%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.